Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance ...
UBS analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $895 to $1080.
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound ...
- Reuters Citing Conf Call
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage...
Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month I...
https://www.youtube.com/watch?v=GFGmukrxZ7Y
